Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Jynneos

Novartis day

Novartis claims first place for its biosimilar Enbrel in US

However, Amgen’s patent infringement lawsuit could delay the launch of Erelzi

Shire Basingstoke

Shire launches dry eye drug Xiidra in US

Sparks rivalry with Allergan’s blockbuster Restasis as first new dry eye treatment in 13 years

- PMLiVE

FDA knocks back Amgen’s chronic kidney disease treatment

Parsabiv was hoped to equal or exceed solid earner Sensipar

Gilead Sciences

Gilead’s Truvada cleared for HIV prevention in EU

May help slow down recent uptick in new HIV diagnoses

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

Sanofi reception

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

FDA verdict on Novo Nordisk’s rival combo Xultophy due next month 

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

- PMLiVE

Novo Nordisk’s Tresiba gaining ground in basal insulin market

Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

- PMLiVE

EMA suspends generic drugs on data integrity concerns

Reports by FDA and WHO find evidence of data manipulation by Semler Research Centre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links